Formulation, Development and Evaluation of Pulsatile Tablets of Etoricoxib
Abstract
Aim: This research aimed to develop a pulsatile drug delivery system (PDDS) for etoricoxib, selective COX-2 inhibitor analgesic, to address the limitations of conventional formulations by releasing the drug at specific intervals aligned with the circadian rhythm of pain.
Method: Core tablets containing Etoricoxib were prepared by direct compression with varied concentrations of croscarmellose sodium as a superdisintegrant. The optimized core tablets were coated using hydrophilic (HPMC K4M) and hydrophobic (ethyl cellulose) polymers in different ratios to create press-coated pulsatile tablets with varying lag times. Physical properties hardness, thickness, friability, and disintegration, drug content uniformity, and in vitro release were evaluated.
Results: The core tablets exhibited rapid drug release, with batch C3 showing 98.61% release within 60 minutes. Press-coated formulations with different polymer ratios exhibited varying lag times, with batch F3 achieving the optimal balance—providing a 4-hour lag time and 96.6% drug release over 8 hours. Stability studies confirmed the physical and chemical stability of the optimized formulation (F3) over 6 months under accelerated conditions.
Conclusion: The developed press-coated pulsatile tablets of etoricoxib successfully achieved a controlled lag time and sustained drug release profile, making them suitable for chronopharmacological management of pain.
Keywords: Etoricoxib, Pulsatile Drug Delivery System, Chronopharmacology, Press-Coated Tablets. etc
Keywords:
Etoricoxib, Pulsatile Drug Delivery System, Chronopharmacology, Press-Coated TabletsDOI
https://doi.org/10.22270/jddt.v14i11.6890References
1. Gandhi BR, Mundada AS, Gandhi PP. Chronopharmaceutics: As a clinically relevant drug delivery system. Drug Deliv. 2011;18(1):1–18. https://doi.org/10.3109/10717544.2010.509358
2. Maroni A, Zema L, Del Curto MD, Loreti G, Gazzaniga A. Oral pulsatile delivery: Rationale and chronopharmaceutical formulations. Int J Pharm. 2010;398:1–8. https://doi.org/10.1016/j.ijpharm.2010.07.026
3. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59:828–51. https://doi.org/10.1016/j.addr.2007.07.001
4. Venkataswamy R, Nallaguntla L. Review article on pulsatile drug delivery system. Asian J Pharm Clin Res. 2021;14(6):48–59. https://doi.org/10.22159/ajpcr.2021.v14i6.41476
5. Jagdale SC, Suryawanshi VM, Pandya SV, Kuchekar BS, Chabukswar AR. Development of press-coated, floating-pulsatile drug delivery of lisinopril. Sci Pharm. 2014;82(2):423–40. https://doi.org/10.3797/scipharm.1301-27
6. Rane AB, Gattani SG, Kadam VD, Tekade AR. Formulation and evaluation of press-coated tablets for pulsatile drug delivery using hydrophilic and hydrophobic polymers. Chem Pharm Bull. 2009;57(11):1213–7. https://doi.org/10.1248/cpb.57.1213
7. Rohini RS. Formulation and evaluation of pulsatile drug delivery system of Pregabalin. Pharm Anal Acta. 2016;7:508. https://doi.org/10.4172/2153-2435.1000508
8. Dabhi C, Randale S, Belgamwar V, Gattani S, Tekade A. Predictable pulsatile release of etoricoxib hydrochloride for chronotherapeutics of arthritis. Drug Deliv. 2010;17(5):273–81. https://doi.org/10.3109/10717541003706240
9. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HN. In-vitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations: A pharmacoscintigraphic study in the beagle dog. Eur J Pharm Biopharm. 2007;67:515–23. https://doi.org/10.1016/j.ejpb.2007.03.002
10. Sawale AV, Jajoo VS, Deshmukh AA. Formulation and evaluation of pulsatile drug delivery system for the treatment of arthritic pain. Res J Sci Technol. 2024;16(3):193–2. https://doi.org/10.52711/2349-2988.2024.00029
11. Ashwini MS, Ahmed GM. Design and evaluation of pulsatile drug delivery of losartan potassium. J Pharm Sci. 2013;12(2):119–23. https://doi.org/10.3329/dujps.v12i2.17610
12. Ishrath A, Devadas V, Ahmed MM. Formulation, development, and characterization of Diltiazem Pulsin Cap for pulsatile drug delivery. Pharm Tech Res. 2019;9(5). https://doi.org/10.46624/ajptr.2019.v9.i5.009
13. Saııgalli ME, Maroni A, Busetti C, Zema L, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of oral systems for time and site-specific delivery of drugs (Chronotopic® technology). Boll Chim Farmaceutico. 1999;138:68–73.
Published
PDF Downloads: 36
PDF Downloads: 9
How to Cite
Issue
Section
Copyright (c) 2024 Rahul S. Radke, Bharat B. Dhore , Ramesh R. Pagore , Kailash R. Biyani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).